^
BIOMARKER:

EGFR wild-type

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR wild-type
NSCLC
durvalumab
Sensitive: B - Late Trials
EGFR wild-type
LUAD
rivoceranib
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
NSCLC
rivoceranib
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
NSCLC
erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
NSCLC
atezolizumab
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
NSCLC
pembrolizumab
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
NSCLC
nivolumab
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
NSCLC
pemetrexed
Sensitive: C3 – Early Trials
EGFR wild-type
NSCLC
cabozantinib tablet
Sensitive: C3 – Early Trials
EGFR wild-type
NSCLC
erlotinib + cabozantinib tablet
Sensitive: C3 – Early Trials
EGFR wild-type
Lung Non-Squamous Non-Small Cell Cancer
tislelizumab
Sensitive: C3 – Early Trials
EGFR wild-type
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
EGFR wild-type
LUAD
REC-4881
Sensitive: D – Preclinical
EGFR wild-type
LUAD
AZD8330
Sensitive: D – Preclinical
EGFR wild-type
LUAD
PF-04691502
Sensitive: D – Preclinical
EGFR wild-type
LUAD
GSK2126458
Sensitive: D – Preclinical
EGFR wild-type
NSCLC
RTB101
Sensitive: D – Preclinical
EGFR wild-type
NSCLC
gefitinib
Sensitive: D – Preclinical